HomeCompareAMED vs ARCC

AMED vs ARCC: Dividend Comparison 2026

AMED yields 1.98% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARCC wins by $1.9K in total portfolio value
10 years
AMED
AMED
● Live price
1.98%
Share price
$100.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$225.10
Full AMED calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — AMED vs ARCC

📍 ARCC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMEDARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMED + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMED pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMED
Annual income on $10K today (after 15% tax)
$168.33/yr
After 10yr DRIP, annual income (after tax)
$191.33/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, AMED beats the other by $190.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMED + ARCC for your $10,000?

AMED: 50%ARCC: 50%
100% ARCC50/50100% AMED
Portfolio after 10yr
$23.5K
Annual income
$113.12/yr
Blended yield
0.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

AMED
Analyst Ratings
8
Buy
18
Hold
2
Sell
Consensus: Hold
Price Target
$143.38
+42.0% upside vs current
Range: $85.00 — $190.00
Altman Z
4.1
Piotroski
7/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMED buys
0
ARCC buys
0
No recent congressional trades found for AMED or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMEDARCC
Forward yield1.98%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$22.6K$24.5K
Annual income after 10y$225.10$1.14
Total dividends collected$2.1K$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$143.38$21.88

Year-by-year: AMED vs ARCC ($10,000, DRIP)

YearAMED PortfolioAMED Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$10,898$198.04$11,373$532.74$475.00ARCC
2$11,863$201.70$12,608$279.46$745.00ARCC
3$12,898$205.19$13,809$142.90$911.00ARCC
4$14,010$208.51$15,042$72.20$1.0KARCC
5$15,202$211.66$16,341$36.27$1.1KARCC
6$16,481$214.65$17,732$18.18$1.3KARCC
7$17,852$217.48$19,231$9.10$1.4KARCC
8$19,322$220.16$20,851$4.55$1.5KARCC
9$20,897$222.70$22,605$2.28$1.7KARCC
10$22,585$225.10$24,504$1.14$1.9KARCC

AMED vs ARCC: Complete Analysis 2026

AMEDStock

Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

Full AMED Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this AMED vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMED vs SCHDAMED vs JEPIAMED vs OAMED vs KOAMED vs MAINAMED vs HTGCAMED vs GBDCAMED vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.